Janssen Vaccines & Prevention B.v.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Biomerieux, Inc.

Janssen Pharmaceuticals, Inc.

Crucell Holland B.v.

Ac Immune Sa

The United States of America As Represented by the Department of Health

Biomerieux Sa

International Aids Vaccine Initiative

Biomérieux Bv

Jaap Goudsmit

Katarina Radosevic

Gabriel Pascual

Robert Anthony Williamson

Jehangir Wadia

Gary J Nabel

Andreas Muhs

Maria Grazia Pau

Nancy J Sullivan

Maria Pihlgren Bosch

Marija Vukicevic Verhille

Charlotte Sadaka

Saroj Raj Ghimire

Donata De Marco

Nicolas Piot

Elizabeth Anne Ramsburg

Pieter Oudshoorn

Vladimir Vladimirovich Lukashov

Suzanne Jurriaans

Edward Norbert Van Den Brink

Cornelis Adriaan De Kruif

Zhi-yong Yang

David T Hickman

Peter L Nara

Bimal Chakrabarti

Robert R Garrity

Wayne C Koff

Cheng Cheng

Govert Johan Schouten

Alphonsus G C M UytdeHaag

Chakkumkal Anish

Clement Asiedu

Jan Henrik Ter Meulen

Cornelis Johannes Andreas Sol

Marcellinus Gualbertus Hubertus Maria Beld

Willem René Boom

Jerald C Sadoff

Jan H Ter Meulen

Liposomes containing tau peptides, preferably phosphorylated tau peptides, and conjugates containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier are described. Pharmaceutical compositions and uses of the liposomes and/or conjugates for treating or preventing a neurodegenerative disease or disorder, such as Alzheimer's Disease, are also described.

Compositions of phosphorylated tau peptides and uses thereof

Methods for inducing an immune response against tau protein in a subject suffering from a neurodegenerative disease, disorder or condition, such as Alzheimer's Disease, are described. The methods include administering a liposomal priming composition containing tau peptides, preferably phosphorylated tau peptides, and a conjugate boosting composition containing tau peptides, preferably phosphorylated tau peptides, conjugated to an immunogenic carrier.

Heterologous administration of tau vaccines

The invention relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The invention also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau

The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.

Antibodies and antigen-binding fragments that specifically bind to  microtubule-associated protein tau

Provided are recombinant adenovirus vectors (serotype 26 and serotype 35) encoding filovirus antigens. The adenovirus vectors can be used to induce protective immune responses against filovirus infection.

Adenovirus serotype 26 and serotype 35 filovirus vaccines

The present invention is related to nucleic acid sequences that can be used in the field of virus diagnostics, more specifically the diagnosis of infections with the AIDS causing Human Immuno-deficiency Virus (HIV). With the present invention nucleotide sequences are provided that can be used as primers and probes in the amplification and detection of HIV-1 nucleic acid. The oligonucleotide sequences provided with the present invention are located in the LTR part of the HIV viral genome. It has been found that, by using the sequences of the present invention in methods for the amplification and detection of nucleic acid a sensitive and specific detection of HIV-1 can be obtained. The benefit of the sequences of the present invention primarily resides in the fact that, with the aid of primers and probes comprising the sequences according to the invention the nucleic acid of all presently known subtypes of HIV-1 can be detected with high accuracy and sensitivity. So far no primer pairs or hybridization probes have been developed that would allow the detection of such a broad range of HIV-1 variants. The oligonucleotide sequences according to the present invention are especially useful in methods for the amplification of nucleic acid.

Nucleic acid sequences that can be used as primers and probes in the amplification and detection of all subtypes of HIV-1

The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.

Nucleic acids encoding modified Ebola virus glycoproteins with diminished cytotoxicity while retaining native antigenic structures

The present invention provides compositions of binding molecules specifically binding to a coronavirus such as SARS-CoV and capable of neutralizing an infection caused by the virus. The compositions are suitable for diagnosing, preventing and/or treating a condition resulting from a coronavirus such as SARS-CoV.

Compositions against SARS-coronavirus and uses thereof

Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector

The present invention provides binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV and can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from SARS-CoV.

Binding molecules against SARS-coronavirus and uses thereof

The present invention relates to novel vaccines containing (whole-inactivated) West Nile Viruses and/or West Nile viral proteins derived therefrom, produced on human cells, wherein the human cells comprise a sequence encoding at least one early region-1 (E1) gene product of an adenovirus. The cells are preferably cultured in suspension to very high densities and under serum-free conditions. Herein, it is disclosed that use of such cells results in high titers of West Nile Virus produced.

Vaccines against West Nile Virus

Growing community of inventors

Amsterdam, Netherlands

Jaap Goudsmit